PHVS News

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Pharvaris Announces Annual General Meeting of Shareholders

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares